Clinical Trial Update: NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery [Phase 1]

View source ↗

Summary

A Phase 1 trial of NT-I7 for recurrent squamous cell carcinoma of the head and neck undergoing surgery was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Resectable Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• NT-I7

Snippet

Sponsor: Hyunseok Kang, MD | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Status: TERMINATED